TNFSF11 Rekombinanter Antikörper

TNFSF11 Rekombinant Antikörper für WB, IHC, Indirect ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

Maus

Anwendung

WB, IHC, Indirect ELISA

Konjugation

Unkonjugiert

CloneNo.

241791B7

Kat-Nr. : 84431-5-PBS

Synonyme

241791B7, CD254, ODF, OPGL, Osteoclast differentiation factor



Geprüfte Anwendungen

Produktinformation

84431-5-PBS bindet in WB, IHC, Indirect ELISA TNFSF11 und zeigt Reaktivität mit Maus

Getestete Reaktivität Maus
Wirt / Isotyp Kaninchen / IgG
Klonalität Rekombinant
Typ Antikörper
Immunogen TNFSF11 fusion protein Eg1956
Vollständiger Name tumor necrosis factor (ligand) superfamily, member 11
Berechnetes Molekulargewicht35KD
Beobachtetes Molekulargewicht22 kDa
GenBank-ZugangsnummerNM_011613.3
Gene symbol Tnfsf11
Gene ID (NCBI) 21943
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Protein A purfication
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

TNFSF11, known as Tumor Necrosis Factor Superfamily Member 11, also known as RANKL (Receptor Activator of Nuclear Factor-κB Ligand), TRANCE, etc., is a member of the Tumor Necrosis Factor (TNF) superfamily.RANKL is a type II homotrimeric transmembrane protein located primarily at the plasma membrane. RANKL is a type II homotrimeric transmembrane protein located mainly at the plasma membrane, and in addition to the membrane-bound form (mRNAKL), it can also be cleaved by proteolytic cleavage of the cell membrane to produce the soluble form (sRANKL). The membrane-bound form of RANKL is the main form involved in triggering the RANKL/RANK signaling pathway and mediating osteoclastogenesis. Current studies have shown that TNFSF11 acts primarily in the immune and skeletal systems and has been implicated in the pathogenesis of degenerative bone diseases, carcinogenesis, and asthma.